FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.

doi:10.2174/1570163817666200518075820

Back to search

Article

FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.

Current cancer drug targets - 1 Jan 2020

Hogan Francesca L, Williams Victoria, Knapper Steven

Abstract excerpt

Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in 30% of acute myeloid leukaemia (AML) patients at diagnosis and confer an adverse clinical prognosis. Mutated FLT3 has emerged as a viable therapeutic target and a number of FLT3-directed tyrosine kinase inhibitors have progr...

Topics

Antineoplastic Agents
Drug Resistance, Neoplasm
Hematopoiesis
Humans
Leukemia, Myeloid, Acute
Mutation
Protein Kinase Inhibitors
Recurrence
Treatment Outcome
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.